Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myelomonocytic, Chronic 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Respiratory Distress Syndrome 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1

Interventions

tocilizumab 1ceftolozane, tazobactam drug combination 1Thoracotomy 1Thoracic Surgery, Video-Assisted 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pneumonia × Immunoglobulin G × Other hematologic neoplasm × Clear all
NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled 10 charts
Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡